期刊文献+

利格列汀联合二甲双胍治疗2型糖尿病患者的临床疗效 被引量:1

原文传递
导出
摘要 目的探讨利格列汀联合二甲双胍治疗2型糖尿病患者的临床效果。方法选取2012年12月至2014年6月朝阳市中心医院内分泌科收治的2型糖尿病患者286例为研究对象,根据口服降糖药情况分为观察组和对照组,每组143例。对照组患者采用安慰剂和二甲双胍治疗,观察组患者采用利格列汀联合二甲双胍治疗,比较两组患者的临床治疗效果及相关不良反应。结果观察组患者治疗总有效率显著高于对照组,不良反应发生率显著低于对照组,差异均有统计学意义(均P<0.05)。结论利格列汀联合二甲双胍治疗2型糖尿病效果显著,具有较高的经济学价值和安全性。
作者 王晓红
出处 《中国药物经济学》 2016年第9期52-53,共2页 China Journal of Pharmaceutical Economics
  • 相关文献

参考文献5

二级参考文献42

  • 1YANG W, LU J, WENG J, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med, 2010, 362(12): 1090-1101.
  • 2DEFRONZA R A. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going [J]. Am J Med, 2010, 123(3 Suppl): S38-S48.
  • 3ZINMAN B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time [J]. Am J Med, 2011, 124 (1 Suppl): S19-S34.
  • 4MOHER D, SCHULZ K F, ALTMAN D. The CONSORT statement: revised recommendation for improving the quality of reports of paralleled-group randomized trials [J]. Ann Intern Med, 2001, 134(8): 657-662.
  • 5AGRAWAL R, JAIN P, DIKSHIT S N. Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor [J]. Curr Drug Targets, 2012, 13(7): 970-983.
  • 6FORST T, UHLIG-LASKE B, RING A, et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus [J]. Diabetes Obes Metab, 2011, 13(6): 542-550.
  • 7DEL PRATO S, BARNETT A H, HUISMAN H, et al. Effect of linagliptin monotherapy on glycaemic controland markers of β-cell function in patients with inadequatelycontrolled type 2 diabetes: a randomized controlled trial [J]. Diabetes Obes Metab, 2011, 13(3): 258-267.
  • 8FORST T, UHLIG-LASKE B, RING A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes [J]. Diabet Med, 2010, 27(12): 1409-1419.
  • 9TASKINEN M R, ROSENSTOCK J, TAMMINEN I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study [J]. Diabetes Obes Metab, 2011, 13(1): 65-74.
  • 10SCHEEN A J. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluatio [J]. Expert Opin Drug Metab Toxicol, 2013, 9(3): 363-377.

共引文献62

同被引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部